ATE193301T1 - Verfahren zur isolierung von proteinen aus milch - Google Patents

Verfahren zur isolierung von proteinen aus milch

Info

Publication number
ATE193301T1
ATE193301T1 AT94910120T AT94910120T ATE193301T1 AT E193301 T1 ATE193301 T1 AT E193301T1 AT 94910120 T AT94910120 T AT 94910120T AT 94910120 T AT94910120 T AT 94910120T AT E193301 T1 ATE193301 T1 AT E193301T1
Authority
AT
Austria
Prior art keywords
milk
interest
isolation
proteins
solubility
Prior art date
Application number
AT94910120T
Other languages
English (en)
Inventor
Julie S Denman
Edward S Cole
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE193301T1 publication Critical patent/ATE193301T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B11/00—Preservation of milk or dairy products
    • A23B11/10—Preservation of milk or milk preparations
    • A23B11/18—Preservation of milk or milk preparations by addition of preservatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/832—Milk; colostrum

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Tea And Coffee (AREA)
AT94910120T 1993-03-09 1994-02-17 Verfahren zur isolierung von proteinen aus milch ATE193301T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2839593A 1993-03-09 1993-03-09
PCT/US1994/001672 WO1994019935A1 (en) 1993-03-09 1994-02-17 Isolation of components of interest from milk

Publications (1)

Publication Number Publication Date
ATE193301T1 true ATE193301T1 (de) 2000-06-15

Family

ID=21843236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94910120T ATE193301T1 (de) 1993-03-09 1994-02-17 Verfahren zur isolierung von proteinen aus milch

Country Status (11)

Country Link
US (1) US5756687A (de)
EP (1) EP0804070B1 (de)
JP (1) JP3801196B2 (de)
AT (1) ATE193301T1 (de)
AU (1) AU693436B2 (de)
DE (1) DE69424687T2 (de)
DK (1) DK0804070T3 (de)
ES (1) ES2146648T3 (de)
GR (1) GR3033500T3 (de)
PT (1) PT804070E (de)
WO (1) WO1994019935A1 (de)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
EP0933029A1 (de) * 1998-02-03 1999-08-04 Xyrofin Oy Magermilchpulverersatz
EP0947464A1 (de) * 1998-04-01 1999-10-06 Single Buoy Moorings Inc. Ladeausleger für Flüssigkeiten mit koaxialen Flüssigkeitsleitungen
US20030005468A1 (en) * 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
NZ511299A (en) * 1998-11-19 2003-02-28 Ppl Therapeutics Scotland Ltd Stabilisation of milk from transgenic animals through expression of a serine proteinase inhibitor and optionally fibrinogen in the mammary gland
US7030289B2 (en) 1998-11-19 2006-04-18 Ppl Therapeutics (Scotland) Ltd Stabilization of milk from transgenic animals
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
AU782069B2 (en) * 1999-05-13 2005-06-30 Gtc Biotherapeutics, Inc. Transgenically produced antithrombin III and mutants thereof
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20040226053A1 (en) * 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
PA8535501A1 (es) 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
WO2002077161A2 (en) * 2001-03-12 2002-10-03 Progenetics Llc Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses
WO2002085924A2 (en) * 2001-04-23 2002-10-31 Abgenix, Inc. ANTI-α3(IV)NC1 MONOCLONAL ANTIBODIES AND ANIMAL MODEL FOR HUMAN ANTI-GLOMERULAR BASEMENT MEMBRANE AUTOANTIBODY DISEASE
JP2005519580A (ja) * 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
NZ529767A (en) * 2001-06-13 2005-10-28 Taurus Hsa Llc Purification of human serum albumin
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
ES2384168T3 (es) * 2002-04-12 2012-07-02 Medarex, Inc. Procedimientos de tratamiento usando anticuerpos CTLA-4
KR100473703B1 (ko) * 2002-08-23 2005-03-10 한미약품 주식회사 형질전환 동물의 젖으로부터 재조합 펩타이드 또는단백질의 정제 방법
TWI268933B (en) * 2003-06-10 2006-12-21 Animal Technology Inst Taiwan Method for separating protein from animal milk
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
WO2005112968A2 (en) * 2004-04-30 2005-12-01 Gtc Biotherapeutics, Inc. Method of using recombinant human antithrombin for neurocognitive disorders
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
JP5112863B2 (ja) 2004-07-01 2013-01-09 ノヴォ ノルディスク アー／エス ヒト抗−ｋｉｒ抗体
RU2342159C2 (ru) 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
JP2008520186A (ja) * 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
LT2620450T (lt) 2005-03-08 2019-02-11 Pfizer Products Inc. Anti-ctla-4 antikūnų kompozicijos
EP3312196B1 (de) 2005-03-23 2019-07-17 Genmab A/S Antikörper gegen cd38 zur behandlung von multiplem myelom
US8323645B2 (en) 2005-03-24 2012-12-04 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
EP1877075A4 (de) * 2005-04-25 2008-07-30 Pfizer Antikörper gegen myostatin
NZ562234A (en) 2005-04-26 2009-09-25 Pfizer P-cadherin antibodies
WO2007019541A2 (en) * 2005-08-08 2007-02-15 Onconon, Llc. Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
KR101536506B1 (ko) * 2005-09-07 2015-07-14 암젠 프레몬트 인코포레이티드 액티빈 수용체 유사 키나제-1에 대한 인간 모노클로날 항체
CN101325971A (zh) 2005-12-07 2008-12-17 米德列斯公司 Ctla-4抗体剂量递增方案
JP5376574B2 (ja) 2005-12-15 2013-12-25 ゲンマブ エー／エス 自己免疫疾患の治療のためのエフェクター機能欠乏抗体の使用
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8071323B2 (en) * 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
WO2008019036A2 (en) * 2006-08-04 2008-02-14 Pharmathene Inc. Long half-life recombinant butyrylcholinesterase
JP5638804B2 (ja) 2006-08-04 2014-12-10 アストラゼネカ アクチボラグ ＥｒｂＢ２に対する抗体
AR062711A1 (es) * 2006-09-08 2008-11-26 Wyeth Corp Lavado de arginina en l a purificacion de proteinas usando cromatografia de afinidad
AU2007302448C1 (en) 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
US8020576B2 (en) * 2006-10-26 2011-09-20 Delaware Capital Formation, Inc. Emergency shutoff valve for use in a fuel dispensing system
US8394927B2 (en) 2006-11-03 2013-03-12 U3 Pharma Gmbh FGFR4 antibodies
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
CA2705164A1 (en) 2007-11-12 2009-05-22 U3 Pharma Gmbh Axl antibodies
US9605035B2 (en) 2008-01-10 2017-03-28 Research Development Foundation Vaccines and diagnostics for the ehrlichioses
PL2285409T3 (pl) 2008-05-30 2016-10-31 Przeciwciała il-1 alfa
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2270053A1 (de) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanisierte AXL-Antikörper
MX366890B (es) 2009-10-23 2019-07-30 Millennium Pharm Inc Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
AU2010340358B2 (en) 2009-12-21 2014-07-24 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
EP2384766A1 (de) 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Neuartiger Antikörper zu einer Carbonsäureanhydrase
EP2580243B1 (de) 2010-06-09 2019-10-16 Genmab A/S Antikörper gegen menschliches cd38
SMT201700547T1 (it) 2010-06-15 2018-01-11 Genmab As Coniugati di farmaco anticorpo umano contro il fattore tissutale
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
SG191781A1 (en) 2010-12-30 2013-08-30 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2729164A4 (de) * 2011-07-07 2015-05-06 Lfb Usa Inc Formulierungen zur stabilisierung von proteinen
US9556281B2 (en) 2011-08-15 2017-01-31 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein A
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
HUE026344T2 (en) 2011-10-11 2016-05-30 Univ Aix Marseille An anti-HIV-1 Tat monoclonal antibody
HK1205522A1 (en) 2011-11-08 2015-12-18 辉瑞公司 Methods of treating inflammatory disorders using anti-m-csf antibodies
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
NZ702282A (en) 2012-04-26 2016-07-29 Univ Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
MY177331A (en) 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
WO2014025546A2 (en) 2012-08-07 2014-02-13 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
US9944992B2 (en) 2013-03-15 2018-04-17 The University Of Chicago Methods and compositions related to T-cell activity
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
CA2916694C (en) 2013-06-28 2023-01-17 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US10611826B2 (en) 2013-07-05 2020-04-07 Laboratoire Français Du Fractionnement Et Des Biotechnologies Affinity chromatography matrix
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
EP3094652B1 (de) 2014-01-13 2021-09-29 Baylor Research Institute Neuartige impfstoffe gegen hpv und hpv-assoziierte erkrankungen
SG10201807826XA (en) 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
JP2017518737A (ja) 2014-04-21 2017-07-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＹＫ標的治療薬のための抗ｐＳＹＫ抗体分子及びその使用
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
AU2015306621B2 (en) 2014-08-27 2021-05-06 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
ES2748295T3 (es) 2014-09-16 2020-03-16 Symphogen As Anticuerpos anti-MET y composiciones
US20180092977A1 (en) 2015-03-18 2018-04-05 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel kcnk9
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
CN108137679B (zh) 2015-08-13 2022-07-19 纽约大学 对Tau的{p}Ser404表位有选择性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
CN108135986B (zh) 2015-08-13 2022-07-29 纽约大学 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
US20190169262A1 (en) 2015-12-04 2019-06-06 Board Of Regents, The University Of Texas System Slc45a2 peptides for immunotherapy
KR102551971B1 (ko) 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 과인산화된 타우에 특이적인 항체 및 이의 사용 방법
CA3031390A1 (en) 2016-07-28 2018-02-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anti- immunoglobulin g aptamers and uses thereof
WO2018049083A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
MA46836A (fr) 2016-11-15 2019-09-25 H Lundbeck As Agents, utilisations et procédés pour le traitement d'une synucléinopathie
EP3555127B1 (de) 2016-12-16 2024-12-18 H. Lundbeck A/S Wirkstoffe, verwendungen und verfahren
WO2018109213A1 (en) 2016-12-16 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Aptamers directed against a kappa light chain-containing protein and uses thereof
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN118047864A (zh) 2016-12-23 2024-05-17 百时美施贵宝公司 用于改进生物分析和生物加工特性的治疗性免疫球蛋白g4的设计
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
WO2018129284A1 (en) 2017-01-05 2018-07-12 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
AU2018300189B2 (en) 2017-07-14 2025-05-15 Pfizer, Inc. Antibodies to MAdCAM
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP3444275A1 (de) 2017-08-16 2019-02-20 Exiris S.r.l. Monoklonaler antikörper anti-fgfr4
CA3081336A1 (en) 2017-10-12 2019-04-18 Gregory LIZEE T cell receptors for immunotherapy
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2019217457A1 (en) 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2021091815A1 (en) 2019-11-04 2021-05-14 Seagen Inc. Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
JP2023500888A (ja) 2019-11-07 2023-01-11 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
EP4069291A1 (de) 2019-12-03 2022-10-12 Evotec International GmbH Interferon-assoziierte antigenbindende proteine und verwendungen davon
JP2023505169A (ja) 2019-12-03 2023-02-08 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｂ型肝炎感染の治療における使用のためのインターフェロン会合抗原結合タンパク質
KR20230004520A (ko) 2020-04-27 2023-01-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 지단백(ａ)에 대한 이소형-비의존성 항체
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
EP4171652A1 (de) 2020-06-29 2023-05-03 Genmab A/S Antikörper-wirkstoff-konjugate gegen den gewebefaktor und deren verwendung bei der behandlung von krebs
EP4175982A1 (de) 2020-06-30 2023-05-10 Fondazione Toscana Life Sciences Neutralisierende antikörper gegen sars-coronavirus-2
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
US20240024320A1 (en) 2020-11-17 2024-01-25 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
EP4351732A1 (de) 2021-06-09 2024-04-17 Evotec International GmbH Interferon-assoziierte antigenbindende proteine zur verwendung zur behandlung oder prävention von coronavirus-infektionen
AU2022377628A1 (en) 2021-10-29 2024-04-11 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2024036265A2 (en) 2022-08-12 2024-02-15 Takeda Vaccines, Inc. Novel anti-denv3 antibodies
WO2024097725A1 (en) 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
IT202300000924U1 (it) 2023-01-23 2024-12-22 Philomena Dove Cucitura all-up leggins seamless
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
IL324556A (en) 2023-05-19 2026-01-01 Servier Lab Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
IT202300015579A1 (it) 2023-07-25 2025-01-25 Fond Toscana Life Sciences Anticorpi contro covid-19 e altri coronavirus umani
WO2025046393A1 (en) 2023-08-25 2025-03-06 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Reagents against human endogenous retroviruses to target cancer cells
IT202300026115A1 (it) 2023-12-06 2025-06-06 Fond Per L’Istituto Oncologico Di Ricerca Ior Una strategia basata su anticorpi che mira ad erg oncogenico attivato nel cancro alla prostata
EP4635983A1 (de) 2024-04-15 2025-10-22 Ymmunobio AG Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5165945A (en) * 1987-07-23 1992-11-24 Schreiber Foods, Inc. Cheese and process and system for making it
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
JPH04365487A (ja) * 1990-04-11 1992-12-17 Consortium Elektrochem Ind Gmbh 組換ｄｎａ−構造体、組換ベクター、トランスゲン動物の乳からの蛋白質の取得法、トランスゲン動物の製法及びトランスゲン動物の乳
US5175013A (en) * 1990-12-31 1992-12-29 The Pillsbury Company Frozen dessert compositions and products
FR2677652B1 (fr) * 1991-06-12 2005-05-27 Agronomique Inst Nat Rech Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee.
US5178894A (en) * 1991-09-26 1993-01-12 Silvia P. Rudel High non-fat milk content bread products having improved keeping qualities

Also Published As

Publication number Publication date
ES2146648T3 (es) 2000-08-16
DE69424687T2 (de) 2000-09-07
JP3801196B2 (ja) 2006-07-26
JPH08510721A (ja) 1996-11-12
WO1994019935A1 (en) 1994-09-15
PT804070E (pt) 2000-11-30
AU693436B2 (en) 1998-07-02
GR3033500T3 (en) 2000-09-29
AU6268394A (en) 1994-09-26
DK0804070T3 (da) 2000-08-07
EP0804070B1 (de) 2000-05-24
EP0804070A1 (de) 1997-11-05
DE69424687D1 (de) 2000-06-29
US5756687A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
DE69424687D1 (de) Verfahren zur isolierung von proteinen aus milch
FI883708L (fi) Menetelmä emäksisten proteiinien eristämiseksi proteiiniseoksista, jotka sisältävät tällaisia emäksisiä proteiineja
ATE144777T1 (de) Brett-stabiles produkt und verfahren zur isolierung der rna, dna und proteine
DE69132098D1 (de) Verfahren zur amplifikation von nukleinsäuren
ATE67498T1 (de) Verfahren zur trennung von folinsaeure.
DE69207228D1 (de) Isolierverfahren von Proteinen durch Ultrafiltration
DE59510976D1 (de) Verfahren zur isolierung von zellinhaltsstoffen, wie nucleinsäuren, aus natürlichen quellen
DE3860816D1 (de) Verfahren zur herstellung von (cyclo) aliphatischen diisocyanaten.
DE69132172D1 (de) Verfahren zur Abtrennung von Blutkomponenten aus Vollblut
DE68907407D1 (de) Verfahren zur sequenzanalyse von dna.
AT400281B (de) Verfahren zur gewinnung von milchproteinen
ATE118508T1 (de) Verfahren zur isolierung von faktor viii.
ATE258598T1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
IS2554B (is) Aðferð til að skilja lípíð og prótein frá líffræðilegu efni
ATE102201T1 (de) Verfahren zur trennung von folinsaeure.
DE3778568D1 (de) Verfahren zur aromatisierung von tabak.
ATE299889T1 (de) Neues verfahren zur trennung von proteinen unter verwendung eines ca++ enthaltenden elutionsmittels
DE59209794D1 (de) Verfahren zur Herstellung von Enzymzubereitungen
FI881496A7 (fi) Menetelmä aminohappojen valmistamiseksi tai uuttamiseksi lannasta
DE69932597D1 (de) Verfahren zur reinigung von prpres aus einem biologischen muster und dessen verwendung
DE3485067D1 (de) Verfahren zur fotometrischen bestimmung der aktivierten partiellen thromboplastinzeit und reagenz dazu.
FI914132A7 (fi) Menetelmä pienen rasvapitoisuuden omaavien koostumusten uuttamiseksi biologista alkuperää olevista aineista
DE69523170D1 (de) Verfahren zur isolierung von molkenproteine
AT388113B (de) Verfahren zur destillativen trennung von gemischen
DE3876098D1 (de) Verfahren zur abtrennung bestimmter proteine aus molke.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification